<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04673643</url>
  </required_header>
  <id_info>
    <org_study_id>taVNS-RE-2020</org_study_id>
    <nct_id>NCT04673643</nct_id>
  </id_info>
  <brief_title>Transcutaneous Auricular Vagus Nerve Stimulation Treatment on Reflux Esophagitis</brief_title>
  <official_title>Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Reflux Esophagitis: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To evaluate the effect of Transcutaneous auricular vagus nerve stimulation for the&#xD;
      patients reflux esophagitis.&#xD;
&#xD;
      Methods: We accrued 29 patients at Beijing TongRen Hospital Affiliated to Capital Medicine&#xD;
      University of. All treatments were self-administered by the patients at home after training&#xD;
      at the hospital. Patients completed questionnaires at baseline and after 4 weeks, 8 weeks, 12&#xD;
      weeks and 24 weeks. Endoscopy, reflux diagnostic questionnaire (RDQ), gastrointestinal&#xD;
      symptom rating scale (GSRS), and SF-36 were performed to evaluate the therapeutic effects. A&#xD;
      difference of P &lt; 0.05 was considered statistically significant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Actual">November 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Transcutaneous Auricular Vagus Nerve Stimulation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from Baseline in the reflux diagnostic questionnaire(RDQ) at 12 Weeks</measure>
    <time_frame>Day 0 and postintervention at Week 12</time_frame>
    <description>The RDQ was used to assess the subjective reflux symptoms covering a 1-wk recall period. RDQ is categorized into four symptom clusters depicting heartburn, chest pain, acid reflux, and food reflux. The total RDQ scores (eight items) were calculated. Patients with RDQ â‰¥ 12 points were considered to have a relapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in the Gastrointestinal symptom scale(GSRS) rating scale at 12 Weeks</measure>
    <time_frame>Day 0 and postintervention at Week 12</time_frame>
    <description>GSRS to measure the subjective gastrointestinal symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in the 36-items Short Form(SF-36) at 12 Weeks</measure>
    <time_frame>Day 0 and postintervention at Week 12</time_frame>
    <description>SF-36 to measure quality of life</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Reflux Esophagitis</condition>
  <arm_group>
    <arm_group_label>taVNS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcutaneous Auricular Vagus Nerve Stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous Auricular Vagus Nerve Stimulation</intervention_name>
    <description>to use taVNS to treat Reflux Esophagitis</description>
    <arm_group_label>taVNS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;=18 and Age &lt;=70.&#xD;
&#xD;
          2. Clinical diagnosis of reflux diagnostic.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of cirrhosis, renal impairment, tumors, thyroid disease, diabetes, Crohn's&#xD;
             disease, or ulcerative colitis.&#xD;
&#xD;
          2. History of GI or abdominal surgery.&#xD;
&#xD;
          3. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>41 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haihong Lian, Doc</last_name>
    <role>Principal Investigator</role>
    <affiliation>BeijingTongren Hospital, Capital Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wu Dong</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 19, 2020</last_update_submitted>
  <last_update_submitted_qc>December 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tongren Hospital</investigator_affiliation>
    <investigator_full_name>wudong0120</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Reflux esophagitis</keyword>
  <keyword>Transcutaneous auricular vagus nerve stimulation</keyword>
  <keyword>Gastroesophageal reflux disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

